Andy Hsieh, an analyst from William Blair, reiterated the Hold rating on Kyntra Bio. The associated price target is $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Andy Hsieh has given his Hold rating due to a combination of factors tied to Kyntra Bio’s strategic focus and current data visibility. The company has realigned around advancing FG-3246, a CD46-targeting ADC in metastatic castration-resistant prostate cancer, supported by an investigator-sponsored Phase Ib/II study in combination with Xtandi after prior ARPI exposure and before chemotherapy.
At the same time, key value inflection points remain pending, including interim results from the Phase II FG-3246 monotherapy trial and the planned Phase III program for roxadustat in lower-risk myelodysplastic syndromes. With Kyntra still evaluating internal versus external development options and awaiting mature rPFS and diagnostic data from the FG-3180 imaging companion, Hsieh sees an insufficient basis to justify a more decisive rating, warranting a Hold stance while these clinical and strategic uncertainties resolve.